Ionis: Dawnzera Approval Kicks Off New Era For Strikingly Undervalued Pharma (NASDAQ:IONS)

Ionis Pharmaceuticals gains momentum with Dawnzera FDA nod, blockbuster potential, key catalysts, and a path to $3B+ revenue by 2030.